Severe Intraocular Infection
Study Details
Study Description
Brief Summary
The host-immune reaction to infection is essential for the comprehension of the disease and the development of new therapies.
The aim of the study is to describe intraocular cytokines network in aqueous humor using multiplex immunoassay, during severe intraocular infection.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Endophthalmitis The diagnosis of endophthalmitis was made on the basis of clinical features including pain, decreased visual acuity (VA), diffuse bulbar conjunctival hyperaemia, chemosis, inflammation of the anterior segment and posterior segment inflammation (all patients had vitreous infiltration diagnosed by biomicroscopy or ophthalmic ultrasound). |
Biological: Cytokines dosage in Aqueous humor
Specify details not covered in associated Arm Description.
|
| Cataract (Control) Controls were patients who underwent cataract surgery. |
Biological: Cytokines dosage in Aqueous humor
Specify details not covered in associated Arm Description.
|
Outcome Measures
Primary Outcome Measures
- Intraocular cytokine network. Intraocular levels of 27 cytokines [Once in the 24 hours following the admission]
Cytokines and chemokines levels in Aqueous humor (AqH) are measured with the Bio-Plex® Multiplex System human Cytokine 27-Plex Panel assay (Bio-Rad, Marne-la-Coquette, France). The immune mediators were classified in five categories: (a) proinflammatory mediators: (IL-6 and monocyte chemoattractant protein (MCP-1), (b) type 1 cytokines: IL-2, IL-12(p70), Interferon (IFN-γ), and tumor necrosis factor-α (TNF-α), (c) type 2 cytokines: IL-4, IL-10 and IL-13, (d) T-regulatory cytokine: IL-10 and (e) Th-17 cytokine: IL-17. The cytokine and chemokine assay plate layout consisted of a standard series in duplicate (1 to 32 000 pg/ml), four blank wells and 20 μl duplicates of pooled AqH samples, diluted to 50 μl with BioPlex mouse serum diluent. The BioPlex® method was performed as recommended by the manufacturer and previously published studies. Data were analyzed with Bio-Plex Manager software® V 1.1 (Bio-Rad).
Secondary Outcome Measures
- Visual acuity [Once in the 24 hours following the admission, then 3 months, 6 months and 1 year]
E Snellen Conversion in LogMAR unit
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Post-operative endophthalmitis
-
Cataract
Exclusion Criteria:
- None
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Service d'Ophtalmologie, Hôpital Pasteur | Colmar | France | 68000 | |
| 2 | Service d'Ophtalmologie, Hôpital Général de Dijon | Dijon | France | 21000 | |
| 3 | Service d'Ophtalmologie, Hôpital Michallon | Grenoble | France | 38043 | |
| 4 | Service d'Ophtalmologie, Centre Hospitalier de Mulhouse | Mulhouse | France | 68100 | |
| 5 | Service d'Ophtalmologie, CHU de Nancy | Nancy | France | 54000 | |
| 6 | Service d'Ophtalmologie, Nouvel Hôpital Civil, Hôpitaux Universitaires de Strasbourg | Strasbourg | France | 67091 | |
| 7 | Service d'Ophtalmologie, Hôpital de Brabois | Vandoeuvre Les Nancy | France | 54511 |
Sponsors and Collaborators
- University Hospital, Strasbourg, France
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 3964